Disease Imaging Nuclear Medicine 
Imaging Technology
NOVEMBER 7, 2024
Under the new policy, CMS will unpackage and pay separately for diagnostic radiopharmaceuticals with per-day costs exceeding $630, removing financial barriers that have long hindered patient access to essential nuclear medicine diagnostic procedures.
AuntMinnie
MARCH 15, 2024
The document was published jointly March 11 in the Journal of Nuclear Cardiology , Clinical Infectious Diseases , the Heart Rhythm Journal , and JACC: Cardiovascular Imaging. The recommendations emphasize the complementary nature of these advanced nuclear medicine exams.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
FEBRUARY 5, 2024
PET imaging using a newly developed radiotracer has identified different patterns of brain tau pathology over time in early-onset versus late-onset Alzheimer’s disease patients, according to a study published February 1 in the Journal of Nuclear Medicine. Image courtesy of the Journal of Nuclear Medicine.
AuntMinnie
JUNE 7, 2024
TORONTO -- AuntMinnie.com spoke with prostate cancer imaging expert Phillip Kuo, MD, PhD, of the City of Hope in Duarte, CA, at the Society of Nuclear Medicine and Molecular Imaging annual meeting about new developments in PET/CT imaging in patients on Lu-177 PSMA-617 therapy. last year for Alzheimer's disease.
Health Imaging
APRIL 11, 2023
“If testing is successful in humans, this would represent an excellent new treatment option for patients with this disease.”
Imaging Technology
JUNE 29, 2023
Based on a novel clustering framework using sparse canonical correlation analysis (SCCA), the integrated approach was successful in identifying four subtypes of Alzheimer’s disease and the top genes associated with each, according to the authors of the study, “An SCCA-clustering framework for Alzheimer’s disease subtyping using tau PET and genomics.”
AuntMinnie
JANUARY 6, 2025
Rates of PET prostate cancer imaging increased rapidly after its approval by the U.S. Food and Drug Administration (FDA), according to a study published January 3 in the Journal of Nuclear Medicine. for those with unfavorable intermediate risk, 14% for those with high risk, and 34% for those with very high-risk disease.
Expert insights. Personalized for you.
97 
Let's personalize your content